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1 INTRODUCTION 
 
Blood-brain barrier (BBB) is a physical barrier between the blood and the brain, which 
function is to maintain brain homeostasis by transporting vital nutrients to the brain but 
at the same time protecting from harmful compounds (de Lange, 2010). The main 
component of the BBB is a monolayer of polarized endothelial cells sealed with tight 
junctions. Many potential drugs for the treatment of diseases of the central nervous 
system (CNS) are unable to reach the brain in sufficient amounts because of this barrier. 
Number of new drug candidates for the treatment of CNS diseases has grown, but only 
few of them enter the market (Pardridge, 2002).  
 
Drugs that are intended to act in the CNS can be administered systemically if they are 
able to pass the BBB or otherwise they need to be introduced directly in the CNS by 
invasive methods. Polymeric, biodegradable nanoparticles can provide one possibility to 
deliver drugs to the CNS by noninvasive way (Wolfart et al, 2012). Nanoparticles are 
submicron sized particles that can be associated with a drug without any modification of 
the drug molecule. Many studies have shown that nanoparticles are able to overcome 
the BBB as well as to produce pharmacodynamic effect on the CNS.  
 
Because of the relatively large size, nanoparticles cannot cross the cell membrane and 
therefore are internalized via endocytosis (Hillaireau and Couvreur, 2009). Endocytosis 
in the brain endothelial cells is not fully understood. It remains unclear, which endocytic 
mechanisms are present in brain endothelial cells, which are their functions and how 
they are regulated (Smith and Gumbleton, 2006 ; Sandvik et al, 2011). Brain endothelial 
cells are polarized in vivo. It is known that cell polarization regulates endocytic 
processes and endocytic activity in the brain endothelial cells is rather low. In this 
study, we wanted to characterize the effect of cell polarization on endocytic pathways in 
human blood brain barrier in vitro model. The characterization of BBB cell model for 
endocytosis aids to employ nanoparticles for targeted brain delivery of molecules across 
the BBB.  
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2 ENDOCYTOSIS AND ITS ROLE IN DRUG DELIVERY 
 
2.1 Types of endocytosis 
 
Endocytosis is an energy-dependent process of cellular ingestion in which the plasma 
membrane folds inward to bring extracellular molecules into the cell (Doherty and 
McMahon, 2009). The main function of the endocytosis is uptake of nutrients, but it 
also controls the composition of the plasma membrane and how the cells interact with 
and respond to their environments. Endocytosis is typically classified into phagocytosis, 
restricted to specialized mammalian cells, and pinocytosis, occurring in all cell types. 
The phagocytosis is uptake of solid particles with diameter of few micrometers and 
pinocytosis is uptake of fluids containing particles in the nanosize range.  
 
The most modern classification of endocytosis in based on lipid rafts (El-Sayed and 
Harashima, 2013). Clathrin-mediated endocytosis (CME) was first described endocytic 
mechanism and it was long thought to be the only pathway (Sandvik et al, 2011). CME 
is also the best studied endocytic mechanism, which takes place in non-lipid raft regions 
of the cell membrane. Lately more pathways have been discovered, such as lipid raft 
dependent endocytosis, which includes caveolae-mediated endocytosis, flotillin-
dependent endocytosis, CLIC/GEEC endocytosis, Arf6-dependent endocytosis and 
RhoA-dependent endocytosis. Phagocytosis and macropinocytosis are endocytic 
mechanisms that transport large particles and are expected to contain both lipid raft and 
non-raft regions of the membrane.  
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Figure 1, Model of different endocytotic mechanisms and intracellular transport in 
the cell. Cargo taken up by endocytosis are enclosed in the vesicles, such as clathrin 
coated vesicles (CCVs), GPI-anchored protein-enriched compartment (GEEC), clathrin-
independent carriers (CLIC), micropinosomes, early endosomes or phagosomes. These 
vesicles with cargo can be matured down the degradative pathway and become 
multivesicular bodies (MVB) which fuse with lysosomes or transported back to its final 
destination. Phagocytosis is restricted to specialized mammalian cell and pinocytosis 
occurs in all cell types (adapted Sahay et al, 2010). 
 
 
2.1.1 Clathrin-mediated endocytosis 
 
Clathrin-mediated endocytosis (CME) is the most studied and the best known endocytic 
mechanism and it is common in most mammalian cell types (Doherty and McMahon, 
2009). CME is vesicular in morphology and it takes place in non-lipid raft regions of 
the cell membrane (Figure 1).  Clathrin is a coat protein that surrounds the cargo in 
endocytotic process and forms coated pits which can be up to 200 nm in size (McMahon 
and Boucrot, 2011). The main scaffold components of the clathrin coat are the proteins 
called clathrin heavy chain (CHC) and clathrin light chain (CLC) (Ungewickell, 1983). 
  
In CME, cargo binds to the transmembrane receptor and is then packaged with the use 
of adaptor and accessory proteins into clathrin-coated vesicles (CCVs), which is then 
internalized (Schmid et al, 2006). Most important adaptor protein is AP2, which links 
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cargo to nucleating clathrin. Accessory proteins participate in CME through helping 
membrane deformation in the membrane bud by recruiting other participating proteins, 
or by performing scaffolding or coordination functions within the endocytic process 
(Doherty and McMahon, 2009).  For instance, N-BAR and BAR domain-containing 
proteins, such as amphiphysin, can generate membrane curvature, bind clathrin  and 
AP2, and recruit dynamin to the budding vesicle (David et al, 1996). However, different 
receptors can use alternative adaptor and accessory proteins for the clustering and 
stimulation of the endocytosis (Doherty and McMahon, 2009). Adaptor and accessory 
proteins can also control the internalization of different cargoes. 
 
Dynamin, the membrane scission protein, is large GTPase, which forms a polymer 
around the vesicle neck, upon hydrolysis (Praefcke and McMahon, 2004).   Dynamin 
mediates the fission of the vesicle from the plasma membrane as well as helps releasing 
the clathrin-coated vesicle (CCV) into the interior of the cell. The clathrin basket is 
released from the vesicle by auxilin and hsc70. Vesicle drifts within the cell and 
delivers its cargo to intracellular compartment.  
 
In most cases cargo taken up by CME ends up in lysosomes but it can also have a role 
in transcytosis (Tuma and Hubbard, 2003). In the cytosol, CCVs begins to lose its 
clathrin coat following formation of an early endosome (El-Sayed and Harashima, 
2013). Cargos inside the endosome can be recycled back to the cell membrane or early 
endosome can be matured into late endosome. Then fusion between late endosome and 
lysosomes occurs to form endolysosome, where degradation of the cargo takes place.  
 
CME takes part of internalization of wide variety of cargoes. Most of the endogenous 
proteins are internalized by CME (Conner and Schmid, 2003). For instance many 
nutrients, such as cholesterol low density lipoprotein (LDL), are taken up into the cell 
by CME (Schmid, 1997). Transferrin is also an example of a cargo that is transported 
through the cell membrane by CME. Transferrin binds to the transferrin receptor and is 
then internalized. Transferrin receptor and transferrin itself are then transported back to 
the surface of the cell membrane for reuse (Harding et al, 1983).  
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2.1.2 Caveolae-dependent endocytosis 
  
Caveolae-dependent endocytosis is common in various cell types, such as fibroblast and 
endothelial cells (Couet et al, 2001). Caveolae-mediated endocytosis is vesicular or 
tubuvesicular in morphology (Figure 1). Caveolae are flask-shape, remarkably stable 
plasma membrane invagitations in size of 50-100 µm. These invagitations are 
associated with lipid rafts. Caveolins, integral membrane proteins, constitute the major 
protein component of caveolae membrane and have a structural role in the formation of 
caveolae. Caveolins also interact with a number of signaling molecules.  Caveolin 1 is 
enriched in caveolae and it binds to cholesterol in lipid raft. Caveolin 1 together with 
caveolin 3 is reguired in caveolae biogenesis (Lipardi et al, 1998). Caveolin 2 is not 
necessary in caveolae formation but it can co-localize with caveolin 1 to form a hetero-
oligomeric complexes (Mora et al, 1999). Cavin, another protein that is included in 
caveolae endocytic machinery, stabilizes caveolae and induces membrane curvature, 
dynamin, which enables vesicle fragment (Hansen et al, 2009; Nabi, 2009).  
 
At the cell surface, caveolae forms a stable functional unit that is generated by 
oligomerized caveolin and associated proteins and lipids (Couet et al, 2001). Also 
during endocytosis caveolar unit is maintained stable (Pelkmans et al, 2004). In 
caveolae-dependent endocytosis, caveolae is first stimulated, for instance by SV 40 
virus or sterols (Sharma et al, 2004). Process is regulated by dynamin, protein kinase C 
and tyrosine kinases (Parton and Simons, 2007). Caveolae form caveolar carriers that 
fuse with the early endosome, or can fuse back to the plasma membrane without the 
involvement of an endosomal intermediate, therefore it may have a role in transcytosis 
(Tuma and Hubbard, 2003). 
 
Folic acid use caveolae-dependent endocytosis to be internalized (Chang et al, 1992). 
Also glycosylphosphatidylinositol (GPI)-enchored proteins, CTB and Shinga toxin are 
mainly internalized through caveolae-dependent endocytosis (Kirkham et al, 2005). 
Even though caveolae is taking a part in endocytosis, it has many other functions, such 
as calcium signaling and other signal transduction events. Some studies suggest that 
under normal, non-stimulated conditions, caveolae are not involved in endocytosis to 
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any significant degree (Thomsen et al, 2002; van Deurs et al, 2003). However, more 
studies are required to understand the whole mechanism and function of caveolae-
dependent endocytosis (Parton and Howes, 2010). 
 
2.1.3 Macropinocytosis 
 
Macropinocytosis is a specific, larger scale pinocytosis that occurs in all cell types with 
only a few exceptions, such as macrophages and brain microvessel endothelial cells 
(Doherty and McMahon, 2012). Macropinocytosis is highly ruffled in morphology and 
GTPase, rac, and actin dependent (Figure 1). In macropinocytosis the invagitation of the 
cell membrane forms a pocket, macropinosome, which pinches off into the cell to form 
a vesicle up to 10 µm in size. Pocket, sized 0.5 - 10 µm, is filled with a large volume of 
extracellular fluid and molecules within it. Macropinosome membrane is formed both of 
lipid raft and non-lipid raft membrane domains (Manes S et al, 1999; Grimmer et al, 
2002). 
 
In macropinocytosis GTP-bound rac stimulates accumulation of actin filaments at the 
plasma membrane and that is involved in plasma membrane ruffling induced by growth 
factors (Ridley et al, 1992). Cholesterol is required for the recruitment of activated rac 
to these sites (Grimmer et al, 2002). Rac activates the Arp2/3 protein complex and 
WAVE, which is a process involved in ruffling (Gao et al, 2007). Many proteins, such 
as ras and Src, kinase PAK1 and arf6, one of the small GTPases, are known to be 
involved in macropinocytosis (Dharmawardhane et al, 2000; Donaldson, 2003; Yarar et 
al, 2007). Solute macromolecules and nutrients are known to be internalized via this 
pathway. 
 
In the cytosol internalized macropinosome loses its actin filaments on its surface.  In the 
majority of the cells, such as macrophages and brain microvascular endothelial cells, 
macropinosomes mature in early endosome, then late endosome or degrade with 
lysosomes (Racoosin and Swanson, 1993; Liu et al, 2002; Mercer and Helenius, 2012). 
In A531 human carcinoma cells, cargo is recycled back to the cell exterior through 
fusion with the cell plasma membrane (Hewlett et al, 1994). Macropinocytosis can also 
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be followed by transcytosis, for instance Shinga toxin through intestinal epithelial cells 
(Lukyanenko et al, 2011). 
  
2.1.4 CLIC/GEEC-type endocytosis 
 
Clathrin-independent carrier (CLIC) / GPI-AP-enriched early endosomal compartment 
(GEEC) endocytosis is dynamin-independent uptake mechanism which takes place in 
lipid rafts of the cell membrane (Lundmark et al, 2008). Mechanism is mediated by 
primary carriers, CLICs, which fuse to form tubular early endocytic compartments, 
GEECs. The small GTPases, Cdc42 and GRAF1, and ADP-ribosylation factors, arf1 
and arf6, induce CLIC/GEEC-type endocytosis (Sabharanjak et al, 2002; Kumari and 
Mayor, 2008; Lundmark et al, 2008). After formation of CLICs, they become acidified 
and acquire Rab5 and EEA1 before fusing to other GEECs or early endosome (Kalia et 
al, 2006). GPI-anchored proteins (GPI-APs) are internalized via this CLIC/GEEC 
uptake mechanism.  
 
2.1.5 Flotillin-dependent endocytosis 
 
Flotillin-dependent endocytosis is common in mammalian cells (Glebov et al, 2006). 
Flotillin-dependent endocytosis is vesicular in morphology and it takes place in raft 
membrane domains (Figure 1). Lipid raft proteins, flotillin 1 and flotillin 2, are 
oligomerized in distinct membrane microdomains, but are not enriched in caveolae. 
Flotillin-dependent endocytosis appears to be both dynamin dependent and independent 
(Glebov et al, 2006; Frick et al, 2007). Cargo is colocalized with flotillin vesicles and 
after internalization it is delivered into late endosome and lysosomes (Payne et al, 2007; 
Riento et al, 2009). Proteoglycan-binding ligands, PEI, LF and PA, enter the cells by 
flotillin-dependent endocytosis.   
 
2.1.6 Phagocytosis 
 
Phagocytosis is an endocytic mechanism that is common in specialized mammalian 
cells, such as macrophages, neutrophils and dendritic cells (Underhill and Goodridge, 
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2012). It transports large solid particles (> 5 µm) into coated vesicles, phagosomes, 
through mechanism that requires actin polymerization. Phagosomes are formed of lipid 
rafts, which are enriched by sphingomyelin and ceratine (Magenau et al, 2011). 
Phagosomes, are shaped according to the shape of particle they engulf. Cargoes can be 
recognized by the “eat me” signals or through opsonisation of the cargo. In cytosol, 
phagosomes fuse to early endosomes and late endosomes, and then fuse to the lysosome 
to form a phagolysosome, where the digestive processing of the cargo takes place 
(Flannagan et al, 2012). 
 
2.2 The role of endocytic pathway in drug delivery 
 
Endocytosis occurs in all cell types in the body and is used to internalize vital molecules 
as well as therapeutic molecules (Doherty and McMahon, 2009). Small and lipophilic 
therapeutic molecules can permeate across the cell membrane by passive diffusion or by 
carrier-mediated diffusion, therefore they do not need endocytosis to be internalized. 
Macromolecular and hydrophilic drugs, such as proteins and peptides, are too large to 
enter the cell by diffusion, therefore they cannot readily cross the cell membrane but are 
internalized via endocytosis. Macromolecular and poorly soluble drugs can also be 
loaded into nanoparticles to be protected or to be intended for targeted drug delivery 
(Hillaireau and Couvreur, 2009).  
 
Certain cell types, such as blood-brain barrier endothelial cells and intestinal endothelial 
cells, carry certain receptors on their surface, which provides the possibility for drug 
targeting (Hillaireau and Couvreur, 2009). Therapeutic molecule or nanoparticle can be 
associated with specific binding moiety to be targeted to the specific receptor and 
internalized via receptor-mediated endocytosis (Wohlfart et al, 2012). For instance folic 
acid and transferrin has been widely used as targeting ligands for nanoparticles (Qian et 
al, 2002; Hilgenbrink and Low, 2005). Different endocytic pathways may lead to 
different endocytic routing and intracellular destiny of the cargo, therefore designing 
nanoparticles specifically targeted to a certain pathway may result in the more specific 
delivery of the drug to certain intracellular compartments. Most of the endocytic 
pathways lead to the delivery of the cargo to endolysosomal compartment (Doherty and 
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McMahon, 2009). Therefore, for cytoplasmic delivery of the drug, it has to be able to be 
released from the endosomes. 
 
In drug delivery, it is important to know whether the drug is endocytosed or further 
transcytosed.  For example, for brain drug delivery of intravenously injected drug, it 
must be transcytosed through the brain endothelial cells in order to reach the brain 
(Gabathuler, 2010). Several pathways including clathrin- and caveolae-mediated 
endocytosis were shown to lead to transcytosis of the drug (Tuma and Hubbard, 2003). 
However, the regulation of transcytosis is poorly understood. For instance in clathrin-
mediated endocytosis, cargo can be degraded in lysosomes or it can be further 
transcytosed through the cell. 
 
2.3 Asymmetry of endocytic processes in polarized cells 
 
Cell polarity is an asymmetrical organization of cellular components and functions and 
it develops through the localization of specific proteins to specific areas of the cell 
membrane (Mellman and Nelson, 2008) (Figure 2). It is implicated in the 
differentiation, proliferation and morphogenesis of cellular organisms and it enables 
cells to perform specialized functions. One example of a polarized cell type is 
endothelial cells, which demonstrates apical - basolateral polarity providing adsorptive 
and protective function in tissue. The establishment and maintenance of the cell polarity 
involves many processes including signaling cascades, membrane trafficking events and 
cytoskeletal dynamics. All these processes need to be well coordinated.  
 
Cell polarity requires polarity regulators, proteins that show roles in polarization 
(Shivas et al, 2010). These proteins form three different complexes at the plasma 
membrane, PAR, Crumbs and Scribble complexes (Mellman and Nelson, 2008). Each 
of these complexes are localizes to a distinct sub-domain of polarized cell. Also 
endocytosis is regulated by different proteins, as described previously. These two 
systems, intracellular trafficking and polarity control, seems to work together by 
crosstalk between polarity proteins and endocytic regulators (Shivas et al, 2010). For 
instance, the PAR complex may promote dynamin-dependent endocytosis, while 
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dynamin-dependent endocytosis may be required to maintain correct localization of the 
PAR complex. 
 
 
 
Figure 2, Endocytosis in polarized cell (right) is more complex than in non-
polarized cell (left). In non-polarized cell, different endocytic mechanisms are not 
regulated as much as in polariced cell. As we can see from the picture: caveolae-
mediated endocytosis is dependent of caveolae, flotillin-dependent endocytosis reguires 
flotillin, clathrin-independent carrier (CLIC) / GPI-AP-enriched early endosomal 
compartment (GEEC) endocytosis (GLIC/GEEC-endocytosis) is dependent of Cdc42 
and GRAF1 proteins, RhoA-dependent endocytosis reguires RhoA and rac1 proteins, 
Arf6-dependent endocytosis reguires arf6 and macropinocytosis occurs by invagitation 
of the cell membrane. Dynamin is GTPase, which is related to several of these 
endocytic pathways. In polarized cell, endocytosis is regulated different manner on 
apical and basolateral membrane of the cell. On apical membrane, clathrin-independent 
endocytosis is known to be regulated by number of factors, such as calmodulin, 
cyclooxygenase, phospholipase D, PKA and PKC, which do not effect on endocytosis 
in basolateral pole. Also caveolae is found only at the basolateral side of the polarized 
cell (adapted Sandvik et al, 2011). 
 
 
In polarized Madin Darby canine kidney (MDCK) cells, clathrin-independent 
endocytosis have been proven to go through differential regulation on the apical and 
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basolateral poles (Eker et al, 1994) (Figure 2). Apical clathrin- independent endocytosis 
is under complex regulation, and can be regulated independently of uptake at the 
basolateral side. Apical clathrin-independent endocytosis can be regulated by a number 
of factors, for example protein kinase A, protein kinase C, phospholipase D, 
cyclooxygenase and calmodulin, that do not affect basolateral uptake. 
 
Most of the knowledge about endocytic mechanisms derives from cells in culture.  
Studies of endocytic mechanisms in cell lines do not directly reflect uptake mechanisms 
in vivo (Sandvik et al, 2008). Cells cultured in on plastic support do not go through 
polarization but on filters polarization occurs. To which extent different endocytic 
mechanisms vary depending on cell polarization is to a large extent not known. 
 
 
3 BLOOD-BRAIN BARRIER AND ITS ROLE IN DRUG DELIVERY 
 
3.1 Structure and function of Blood-Brain Barrier  
 
Blood-Brain Barrier (BBB) consists of specialized capillary endothelial cells 
surrounded by astroglial endfeet and pericytes (de Lange, 2012) (Figure 3). Specialized 
capillary endothelial cells (BBB) form barrier function by tight junctions between the 
cells. BBB intercepts the blood and the brain protecting the brain from harmful 
compounds but allowing vital nutrients to pass. It therefore has a role to maintain the 
neuroparenchymal microenviroment. 
 
 
Figure 3. The blood-brain barrier (adapted Cordoso et al, 2010). 
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Capillaries in the brain are around 50-100 times tighter than in the periphery due the 
tight junctions tightly sealing polarized endothelial cells (Abbott et al, 2008). Tight 
junctions are composed of transmembrane proteins and peripherally tight junction 
associated proteins, such as zonula occludens proteins (ZO-1, -2 and -3), occludins, 
claudins and adhesion molecules (Wolburg and Lippoldt, 2002). ZO-proteins are 
submembranous tight junction-associated proteins that take a part in signal transduction 
and in anchoring the transmembrane tight junction proteins to the cytoskeleton. 
Occludins are not required for the formation of tight junctions, but rather needed for 
regulating the barrier properties by sealing the tight junctions (Lacaz-Vieira et al, 1999). 
Claudins are important in formation of barrier properties (Tsukita and Furuse, 1999; 
Tsukita and Furuse, 2000). Adhesion molecules, such as the junctional adhesion 
molecules (JAM) are involved in organizing the tight junctional structure (Martin-
Padura et al, 1998; Dejana et al, 2000)  
 
Many signalling pathways have been shown to be involved in tight junction regulation 
(Wolfburg and Lippoldt, 2002). All these proteins together with capillary endothelial 
cells form a tight barrier with transendothelial resistance (TEER) over 1000 Ω·cm² (Butt 
et al, 1990). TEER of other capillaries is much less. For instance human umbilical 
endothelial cells (HUVEC) reach TEER of 25 Ω·cm² (Ali et al, 1999).  Tight junctions 
regulate paracellular transport as well as also help on maintenance of cell polarity in 
BBB.  
 
Cerebral endothelial cytoplasm has many enzymes, which have important role in blood-
brain barrier as a metabolic barrier (de Lounge, 2012). Cytochrome P450 enzymes 
(CYPs), CYP1B1 and CYP2U1, are the most expressed enzymes in brain microvessels 
(Dauchy et al, 2008). The role of these enzymes is not yet fully understood, but they 
take a part in drug metabolism.  Differences in the amount of various enzymes at both 
sides of the cell membrane seem to contribute to the polarity of endothelial function in 
the control of the BBB (de Lounge, 2012).  Plasma membrane of brain endothelial cells 
exhibits many transporters, such as P-glycoprotein (P-gp), multidrug resistance 
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associated protein (MRP) 1 and 4, and breast cancer resistance protein (BCRP), to 
maintain the homeostasis of the brain. 
 
Basement membrane (also called basal lamina) is a thin layer of a specialized 
extracellular matrix that form a supporting structure surrounding the brain capillary 
endothelial cells which consist of number of collagens, laminin, fibronectin, antactin, 
thrombostin, heparin sulfate and chondroitin sulfate proteoglycans (Vorbrodt et al, 
1988; Paulsson, 1992; Erickson and Couchman 2000). It provides mechanical support 
for cell attachment and it can act as a barrier to the passage of macromolecules. It also 
provides base for the cell migration and separates adjacent tissue 
 
Astrocytes are glial cells that provide cellular link to the neurons (Abbott et al, 2006). 
Astrocytes participate on induction of blood-brain barrier properties of endothelial cells 
and they also have a role in synaptic activity, cerebral blood flow and metabolism. 
Pericytes are contractile cells surrounding endothelial cells of capillaries. Pericytes help 
to sustain blood-brain barrier, but also maintain homeostatic and hemostatic functions 
(Krueger and Bechmann, 2010). They play a role in blood-brain barrier integrity, 
angiogenesis, neovascularization and regulation of cerebral blood flow.  
 
3.2 Significance of BBB in drug delivery 
 
The number new drugs developed for treatment of CNS diseases has grown, but only 
few are on the sale (Pardridge, 2002). This is due the permeation limiting BBB, which 
restricts transport of many potential drugs to the brain in sufficient concentrations. The 
main reason for the limited transfer of drugs to the brain is tight junctions. Also 
enzymatic barrier and efflux transporters expressed in the cerebral endothelium restrict 
drugs transport to the brain. 
 
Potential drugs can permeate across the brain endothelium by several routes (Abbott et 
al, 2008). Nonpolar, small lipophilic drugs and gaseous molecules can diffuse passively 
through the BBB (Abbott et al, 2004). Drugs that cannot be diffused, can be transported 
to the brain via carrier-mediated transporters or via endocytosis (Pardridge 2007; 
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Dobson and Kell, 2008). For instance, glucose and small peptides can be transported to 
the brain via carrier-mediated influx transporters and macromolecules via transcytosis 
(Abbott et al, 2008). Some diseases, such as brain tumors and multiple sclerosis (MS), 
can affect barrier properties of the BBB. Disease state can modulate the tight junctions 
and open the paracellular pathway and therefore increase the transport of drugs to the 
brain. 
 
Therapeutic molecules, which are bigger than 500 Daltons and hydrophilic, can be 
delivered to the brain by effective drug delivery strategies. Invasive drug delivery 
methods include temporary increase of the blood-brain barrier permeability, for instance 
by the osmotic disruption, and intra - cerebroventricular (ICV) and intracerebral 
implants (Neuwelt et al, 1979; Chauhan, 2002; Westphal et al, 2006). These strategies 
are rather expensive and they are associated with high risk of complications. Also most 
of the invasive strategies rely on diffusion, which is poor mode of drug delivery to the 
brain (Pardridge, 1997). 
 
Another strategy to overcome the BBB is the lipidization of the drug molecule. 
Hydrophilic drug can be conjugated to lipid carriers (Prokai –Tatrai et al, 1996). 
Lipidization increases the uptake of the drug in the brain, but also to other tissues in the 
periphery, which is a disadvantage of this strategy. Small hydrophilic drugs can be 
transported to the brain via carrier-mediated transport within the brain capillary 
endothelial plasma membrane, if the drug can be structurally altered to mimic an 
endogenous nutrient (Pardridge and Oldendorf, 1977). Large molecules, such as insulin, 
can be transported through the BBB by receptor-mediated transport. Drug molecule can 
be bound to endogenous ligands, but many times these ligands have serious side effects. 
As described further, good strategy to take advantage of endogenous transport systems, 
is the use of nanoparticles, which are internalized via endocytosis.  
 
3.3 In vitro models of blood-brain barrier 
 
As discovery and development of CNS drugs are extensively growing, the development 
of comparatively simple, stable and reproducible in vitro BBB permeability model is an 
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increasing need (Alavijeh et al, 2005). In vivo preparations maintain the brain cellular 
and fluid compartments, as well as the cerebral blood flow. However, in vivo 
preparations involve surgical skill and are relatively low throughput. Animal models are 
also expensive and they are involved in many ethical issues.  In vitro BBB cell models 
provide high throughput and can be used in many kind of drug testing, for instance in 
drug distribution and drug permeability studies.  Blood-brain barrier in vitro models are 
also important in structural studies of BBB. Evaluating the ability of the drug to 
penetrate via BBB  is important not only for the targeting the drug to CNS, but also for 
other drugs due to toxicity issues.  
 
Good and well predictive in vitro BBB cell model to be exploited for the 
transendothelial BBB permeability screening of potential CNS drugs must exhibit many 
requirements. BBB cell model must display reproducible solute permeability and 
restrictive paracellular barrier properties (Gumbleton and Audus, 2001; Abbott et al, 
2008). It allows ease of culture meeting the time and technical requirements, such as 
grow time, good viability and show little change in phenotype following passage. Good 
in vitro BBB cell model also has realistic cell morphology, high cell purity and 
functional expression of most important transporters.  
 
3.3.1 Primary/low passage cultures  
 
Primary or low passage cultures of brain capillary endothelium are close to the in vivo 
cell phenotype and can provide remarkable amount of isolated brain capillary 
endothelial cells (Gumbleton and Audus, 2001). Mostly used species are bovine and 
porcine. These cultures generate a restrictive paracellular barrier properties as TEER is 
approximately over 500 Ω·cm². However, time and technical resource required for 
isolation as well as reproducibility in phenotypic properties makes the primary/low 
passage cultures challenging. Also non-human origin makes molecular characterization 
difficult.  
 
Bovine brain microvessel endothelial cells (BBMEC) are commonly used as a primary 
or low passage culture in BBB in vitro model (Abbott et al, 2008). Bovine brains yield 
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around 100 viable cells and monolayer of BMEC maintains many morphological and 
biochemical properties as the BBB in vivo (Audus and Borchardt, 1986; Audus and 
Borchardt, 1987; Pal et al, 2007). BMEC are functionally polarized as bovine brain 
microvessel endothelial cells in vivo and it can develop restrictive paracellular barrier. 
These features are found to decline in culture and following passage (Abbott et al, 
2008). Co-culture BMEC with astrocytes or exposure to astrocyte-conditioned medium, 
can induce and maintain the tightness of the monolayer and this type of model has been 
the most successful. TEER of the BMEC has reported to be approximately 180 Ω·cm² 
but when co-cultured with astrocytes it was 10 times higher (Wolburg et al, 1994).  
 
Porcine brain microvessel endothelial cells (PBMEC) are one of the most used 
primary/low passage cultures of BBB in vitro model (Abbott et al, 2008). PBMEC can 
develop tight cell monolayer when serum is removed and replaced with hydrocortisone 
(Franke et al, 1999). Hydrocortisone seems to increase the tight-junctional barrier. 
TEER of the PBMEC have been approximately 600-800 Ω·cm². As the other primary 
and low passage cultures, PBMEC exhibits many characteristics similar to the BBB in 
vivo.  
 
Murine brain microvessel endothelial cells (MBMEC) co-cultured with rat astrocytes 
provide in vitro BBB cell model with transendothelial resistance of 200 Ω·cm² (Shayan 
et al, 2011). MBMEC also show high barrier properties in sodium fluorescein 
permeability test and in expression of specific tight junction proteins, such as occludin 
and claudin. Astrocytes seem to be responsible of these barrier properties in this model. 
MBMEC provide relevance to in vivo models in drug industry, but the TEER is many 
times lower than in other primary/low passage cultures. 
 
3.3.2 Immortalized cell lines 
  
A number of immortalized brain capillary endothelial cell lines have been generated 
(Gumbleton and Audus, 2001). Immortalization allows for ease of culture. So far, 
immortalized cell lines are rather leaky due the absence of the necessary restrictive 
paracellular barrier properties which does not allow their effective use in 
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transendothelial permeability screening. However, these cell lines can be good for drug 
uptake and efflux studies, because they express the typical BBB transporters. For 
instance, immortalized cell lines can be used in nanoparticle uptake studies as 
nanoparticles are too big to penetrate in between the cells even though the tight 
junctions are not so tight (Hillaireau and Couvreur, 2009). 
 
bEND3 and bEND5 cells, derived from mice, are commercially available and can be 
used in transport studies (Gumbleton and Audus, 2009). Well characterized, rat derived 
RBE4 cell line expresses the typical endothelial markers and shows differentiation of a 
brain endothelial phenotype in the presense of astroglial factors (Gumbleton and Audus, 
2001). Human based SV-HCEC cell line expresses many properties of primary/low 
passage brain capillary cells, but does not develop a sufficient paracellular barrier 
(Muruganandam et al, 1997; Kannan et al, 2000).  However, all these immortalized cell 
lines have failed to develop the necessary paracellular barrier that would allow its use as 
a good in vitro BBB transendothelial permeability tool.  
 
So far, immortalized human brain endothelial cell line hCMEC/D3 is the best 
characterized human BBB cell line (Poller at al., 2008). hCMEC/D3 cells has been 
developed by immortalization of primary human brain capillary endothelial cells 
(BCEC) through coexpression of h-TERT antibody and SV40 large T antigen via a 
lentiviral vector system (Weksler, 2005). Human brain tissue has been obtained from 
the temporal lobe of an adult female.  
 
Weksler and collegues (2005)  perfomed the detailed characterization of hCMEC/D3 
cell line. Morfology of the hCMEC/D3 cell line appeared to be similar to primary 
cultures of brain endothelial cells. Cell line showed no senescence or dedifferentiation 
during over 100 population doublings. Maintenance of nontransformed phenotype is 
significant characteristic of this cell line. No other human derived cell line has showed 
to maintain nontransformed phenotype during doublings (Gumbleton and Audus, 2001). 
Expression of many endothelial markers, such as cellular junction associated proteins 
PECAM-1 and VE-cadherin and cytoplasmic granules of von Willebrand factor, has 
been showed (Weksler et al, 2005). Also β- and γ-catenins and F-actin were expressed. 
18 
 
No change was detected in endothelial markers when passaging the cells. Based on 
these results, hCMEC/D3 cell line displays close phenotype to normal primary 
endothelial cells. 
 
Even though hCMEC/D3 has a leakier phenotype than the in vivo BBB, hCMEC/D3 
cell line has a good permability correlation (R=0.938) between in vitro and in vivo data 
(Weksler et al, 2005). Correlation has been evaluated by in vitro/in vivo comparisons for 
some markers of low and high passice permeability. Permeability range in the cell line 
have been roughly 0.5 – 5.5 ·     cm/s, which is far from the in vivo situations (Poller 
et al, 2008). However, it has been noticed that human serum (HS) increases the 
tightness of the monolayer, when changing the fetal calf serum (FCS) to HS (Poller et 
al, 2008).  
 
hCMEC/D3 expresses many of the most important transporters similar to that in 
isolated brain microvessels (Weksler et al, 2005; Poller et al, 2008; Dauchy et al, 2009). 
ATP-binding cassette (ABC) efflux transporters, which includes P-glycoprotein (P-gp, 
also called ABCB1 and MDR1), breast cancer resistant protein (BCRP, also called 
ABCG2) and multi resistant proteins (MRPs), such as MRP1, MRP3, MRP4 and 
MRP5, are expressed in hCMEC/3 cells (Dauchy et al, 2009). At least P-gp, BCRP and 
MRP1 have been proved to be functional (Dauchy et al, 2005; Weksler et al, 2005). 
 
Some phase 1 cytochrome P450 (CYP) enzymes has been detected from hCMEC/D3 
cells (Dauchy et al, 2009). CYP2U1 is main enzyme expressed in the cells. Also 
CYP2S1 and CYP2R1 are expressed but lesser extent. CYP2U1 is involved in 
arachidonic acid and other long chain fatty acid metabolism while CYP2S1 is 
metabolizing naphthalene and CYP2R1 is taking a part in vitamin D metabolism. The 
role of these enzymes is not fully understood. As hCMEC/D3 cells exhibits many of the 
characteristics that are essential for good and predictive BBB in vitro model, it can be 
one of the most promising tool for BBB studies.  
 
In addition, also surrogate, immortalized cell lines have been used in vitro studies of 
active transport (Summerfield et al, 2007; Hellinger et al, 2012). Continuous cell lines 
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of non-cerebral origin are commercially available and they exhibit at least some of the 
criteria required for an in vitro BBB permeability model. Canin renal epithelial cell line, 
MDCK, transfected with the human P-glycoprotein (Pgp) gene, MDR1, has been used 
as a surrogate BBB model (Summerfield et al, 2007; Hellinger et al, 2012). Human 
colon carcinoma derived Caco-2 cell naturally express Pgp and it has been used in 
permeability and efflux studies (Hellinger et al, 2012). Both cell lines have better TEER 
values than the cells obtained from the brain tissue and they have shown good integrity, 
but unnatural transporter expression and epithelial lineage makes it questionable if these 
cell lines gives reliable data. 
 
3.3.3 Dynamic three-dimensional BBB model 
 
Fluid flow through the endothelial cells in vivo exerts shear stress across the apical 
surface and induces factors from astrocytes, which have influence on functional 
differentiation of brain endothelial cells (Rizzo et al, 1998; Santaguida et al, 2006). 
Dynamic three-dimensional in vitro BBB model mimics functionally and anatomically 
the microvasculature and enables the co-culture of brain endothelial cells and astrocytes 
inside porous fiber tubes or scaffolds, and incorporation of fluid flow pathway via the 
lumen. This model generates TEER of roughly 2000 Ω·cm². The model appears also to 
display polarized functional expression of transporters and receptors characteristic in 
the BBB. 
 
Bovine aortic endothelial cells co-cultured with glial cells were first used in this kind of 
dynamic BBB cell model (Stanness et al, 1997; Cucullo et al, 2002). Good BBB 
characteristics has been demonstrated also with mouse bEnd3 cells with and without 
astrocytes (Booth and Kim, 2012; Prabhakarpandian et al, 2013).  Also the hCMEC/D3 
cells have been shown to perform well in this system (Cucullo et al, 2008; Griep et al, 
2013). Three-dimensional BBB model would have great benefit in cell studies, but due 
the technical demands, it may not be the best model for a high throughput permeability 
screening.  
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3.3.4 Human endothelial cells derived from human pluripotent stem cells 
 
Recently, endothelial cells derived from pluriporent stem cells (hPSCs) have been 
demostrated as an in vitro BBB cell model (Lippmann et al, 2012). hPSC cells have 
been co-differentiated with neural cells and followed by purification of the BBB-like 
endothelial population on selective matrix. These endothelial cells have many BBB 
properties similar to those of brain microvessel endothelial cells (BMECs). They 
develop tight-junctions and express the most important transporters as well as polarized 
efflux transporters. Most importantly, these endothelial cells could be capable on 
transport studies, due the barrier and transport properties. BBB endothelial cells 
differentiated from hPSCs have transendothelial electrical resistance 1450 (±140) 
Ω·cm² and they are relatively easy to culture, which makes this type of models 
potentially promising.  
 
3.3.5 Human umbical vein endothelial cells 
 
Langford and colleagues (2005) have demonstrated a human based blood-brain barrier 
in vitro cell model using human umbical vein endothelial cells (HUVEC). These cells 
are derived from the endothelium of veins from the umbilical cord. HUVEC were 
cultured with fibroblast growth factor 2 (FGF2) which is produced by astrocytes. FGF2 
promotes endothelial cell fitness, angiogenesis and maintains the integrity of the BBB. 
It seems that FGF2 is needed to produce tight barrier properties in HUVEC. There is 
lack of information about this cell line, but the advantage of this cell line is the human 
origin.  
 
Overall, development of a well predictive BBB cell model has proven hard. Primary or 
low passage cultures exhibits many of the characteristics of the BBB in vivo, but they 
have inter-batch variability in expression of tight junctions, transporters, enzymes and 
receptors (Abbott, 2004; Abbott, 2007). Immortalized cell lines provide ease of culture 
but fail to generate tight monolayer (Gumbleton and Audus, 2001). Tridimensional 
models develop tight monolayer, express the most important transporters and enzymes, 
but are not suitable for high throughput screening.  
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3.4 Nanoparticles as tools for drug delivery through BBB 
 
Nanoparticles are submicron sized particles, colloidal carriers, which can be associated 
with a drug molecule (Faraji and Wipf, 2009). Variety of materials, including polymers, 
lipids and inorganic compounds, can be used in formation of nanoparticles (Figure 4). 
Nanoparticles can improve the pharmacokinetic properties of the drug due the longer 
self-lives, higher stability and possibility to better control of drug release, which leads to 
better efficacy and reduction  in side effects (Kreuter et al, 1995). Nanoparticles, which 
are intended for parenteral use, have to be biodegradable and nontoxic. 
 
 
 
Figure 4, Different kind of nanoparticles used in drug delivery. (adapted Faraji and 
Wipf, 2009). 
 
 
Due to relatively large size and hydrophilic nature, nanoparticles cannot cross the cell 
membrane and they are mainly internalized via endocytosis. Successful size seems to be 
150-300 nm and this size is mainly internalized by clathrin-mediated endocytosis 
(Hillareu and Couvreur, 2009). Nanoparticles over 500 nm are using caveolae-mediated 
endocytosis. Internalization mechanism depends on particle size, surface charge and 
hydrophobicity of the particle (Wohlfart et al, 2012). Positively charged nanoparticles 
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are internalized faster because of the negatively charged cell membrane. Endocytosis of 
the nanoparticle seems to be also cell type dependent (Sahay et al, 2010). Surface 
modification of the nanoparticle is important, because it have an effect to the solubility, 
stability and a targeting of the nanoparticle. Nanoparticles (NPs) can serve a promising, 
non-invasive tool to deliver drugs through the BBB. Many studies have proven that 
different kinds of surface modified nanoparticles are able to entry into the brain after 
intravenous injection via endocytosis (Wohlfart et al, 2012). This strategy does not 
involve any modification of the drug molecule, which is also important advantage. 
 
3.4.1 Polymeric nanoparticles  
 
Polymeric nanoparticles are biodegradable and biocompatible (Faraji and Wipf, 2009) 
(Figure 4). Polymeric nanoparticles can be engineered various ways and usually they 
are surface modified for instance with gelatin, chitosan and polyethylene glycol (PEG). 
Surface modification improves the pharmacokinetic control, stability and the efficacy of 
the nanoparticle. PEG reduces immunogenicity and phagocytosis of the macrophages, 
which increases the blood level of drug in organs, such as in the brain (Alyautdin et al, 
1997; Alyautdin et al, 2001; Kreuger et al, 2003). Polymer matrix prevents drug 
degradation and can provide controlled drug release. 
 
Poly(butyl cyanoacrylate) (PBCA) is the most studied nanoparticle to be used drug 
transport to the brain (Wilson, 2009). PBCA is low molecular weight polymer with 
relatively low toxicity and very rapid biodegradability. PBCA with polysorbate 80 (PS 
80)  has been shown to pass the BBB both in vitro and in vivo and it has been used to 
deliver wide variety of drugs to the brain (Kreuter et al, 1995; Kreuter et al, 2002, 
Wilson, 2009). Uptake mechanism is not fully understood, but it has been proposed to 
happen via receptor-mediated endocytosis (Kreuter et al, 2005). Absorption of 
apolipoprotein associated PS 80 coated PBCA has been also demonstrated in vivo 
(Kreuter et al, 2002). Effect of PBCA seems to be dependent of the surface modification 
as PBCA without PS 80 does not have any effect on internalization of drugs to the 
brain. 
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A few studies have been performed using poly(lactide-co-glycolide) (PLGA) as a 
nanocarrier in brain delivery of drugs (Wohlfart et al, 2012). PLGA is a synthetic 
material which internalization seems to be cell type and surface charge dependent 
(Vasir and Labhasetwar, 2008). Surfactant coated PLGA-PEG-PLGA (PEP) 
nanoparticles showed  improved transport of loperamide through the BBB in vitro and 
in vivo (Cheng et al, 2013). Internalization occurred by receptor mediated endocytosis. 
Cheng et al also demonstrated that PEP without surfactant coating did not improve the 
internalization of loperamide. Also poly(methoxypolyethyleneglycol cyanoacrylate-co-
hexadecylcyanoacrylate (PEG-PHDCA) have been investigated to be transported to the 
brain in vitro and shown to be internalized via clathrin-mediated endocytosis (Kim et al, 
2007).  
 
3.4.2 Solid lipid nanoparticles 
 
Solid lipid nanoparticles (SLNs) are lipid-based submicron sized colloidal carriers that 
consist of lipid core surrounded by monolayer of phospholipids and further stabilized by 
surfactants (Faraji and Wipf, 2009) (Figure 4). Due to ease of biodegradation, solid lipid 
nanoparticles are less toxic than polymeric nanoparticles and their pharmacokinetic 
profile can be easily engineered with core design. Surfactant amount affects to the 
release profile of the drug payload. 
 
Many studies have been made to demostrate that solid lipid nanoparticles are able to 
overcome the BBB. For instance, risperidone-loaded solid lipid nanoparticles have been 
investigated to be transported to the brain by intranasal route in vivo (Patel et al, 2011). 
Venishetty and collegues (2013) demonstrated the increased transport of 
betreliesoxybutyric acid (HBA) grafted docetaxel loaded solid lipid nanoparticles (HD-
SLNs) to the brain via monocarboxylic acid transporter (MCT1) in vitro and in vivo. 
Also Martin et al (2012) demonstrated the uptake of antitumor medicine, camptothecin, 
loaded SLNs to the brain both in vitro and in vivo.  
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3.4.3 Liposomes 
 
Liposomes are bilayered vesicles surrounded by a phospholipid membrane (Faraji and 
Wipf, 2009) (Figure 4). Liposomes are amphiphilic in nature, easy to surface modifiable 
and biocompatible. They are also able to deliver large amounts of drug to the tissue. 
Disadvantage of liposomes is the limited biological stability, which can be though 
improved by PEGylation, which allows longer residence time and better control of drug 
delivery. Wide variations of drugs have delivered to the brain by liposomes. Targeted 
liposomes have been investigated to deliver drugs to the brain (Schnyder and Huwyler, 
2005). Boado and Pardridge (2011) have also demonstrated efficient gene transfer to the 
brain by Trojan horse liposomes (THL), which are pegylated liposomes containing 
plasmid DNA in the interior of the liposome. THLs were specifically targeted to the 
receptors on the BBB by peptidomimetic monoclonal antibody and were transported 
through the BBB via receptor-mediated transcytosis as well as endocytosed into the cell 
and the brain cell nuclear compartment. 
 
3.4.4 Inorganic nanoparticles 
 
Inorganic nanoparticles are typically composed of silica and alumina, but also metals, 
metal oxides and metal sulfides are used (Faraji and Wipf, 2009) (Figure 4). Particle 
size, shape and porosity can be modified when producing inorganic nanoparticles of 
these materials. Relatively easy surface modification of these nanoparticles and stability 
in broad range of temperature and pH, are the major advantages of inorganic 
nanoparticles. For instance, Yim and coworkers (2012) have demonstrated the 
penetration of serum albumin surface coated magnetic metal ferrite nanoparticles 
through the BBB, both in vitro and in vivo. Also gold nanoparticles have been 
demonstrated to pass the blood-brain barrier in vivo (Sonavane et al, 2008). Based on 
results, penetration of gold nanoparticles to the brain was particle size-dependent. Only 
smaller nanoparticles in size of 15 and 50 nm were able to penetrate through the BBB, 
while bigger nanoparticles in size of 100 and 200 nm were not able to pass the BBB. 
However, the non-biodegradability and slow dissolution limits the use of these 
nanoparticles as a drug delivery tool to CNS. 
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3.4.5 Other nanoparticles  
 
Nanotubes are sheets of atoms arranged in tubes and usually they are made of soluble 
fullerene derivatives (Faraji and Wipf, 2009) (Figure 4). Nanotubes serve large internal 
volumes and the external surface can be easily functionalized. However, due to the 
potential toxicity, they are not useful in nanoparticulate brain delivery. Dendrimers are 
macromolecules formed from monomeric or oligomeric units of polymers. They 
provide many advantages, such as ease of modification, size control and the potential to 
create an isolated active site core area. Dendrimers have been proven to across the BBB 
in vitro but they need to be improved in biocompatibility and cytotoxicity profiles 
(Dhanikulaet al, 2008). Nanocrystals are molecule aggregates that can be combined into 
a crystalline form of the drug surrounded by a coating of surfactant (Faraji and Wipf, 
2009). Also nanocrystals are potentially toxic, but it can be reduced by surfactant 
coating. Use of nanocrystals as nanomedicines in drug delivery is limited due the 
limited stability and the requirement of crystallization of the therapeutic compound. 
 
 
4 AIM OF THE STUDY 
 
The aim of this work was to characterize the effect of cell polarization on endocytic 
pathways in human blood brain barrier in vitro model. The more specific aims were (1) 
to demonstrate the cell polarization and (2) to characterize the expression, localization 
and functionality of endocytic pathways in polarizing human brain endothelial cells. 
Immortalized, human hCMEC/D3 brain endothelial cells were chosen for this study as 
this cell line displays well the in vivo characteristics of BBB and is suitable for 
nanoparticle uptake studies (Gumbleton and Audus, 2001). 
 
Four different approaches were utilized to characterize the level of cell polarization at 
multiple time points. First, tightness of the endothelial layer was evaluated by lucifer 
yellow permeability assay and by measurement of transendothelial electrical resistance 
(TEER). Second, expression of alkaline phosphatase, the marker enzyme of 
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differentiated BBB phenotype, was demonstrated. Third, expression of specific tight 
junction protein, ZO-1, was observed by confocal microscopy after immunostaining.  
 
To characterize hCMEC/D3 cells for the presence of specific endocytic pathways, 
proteins involved into each pathway were selected. Expression of these proteins at 
mRNA level was assessed by quantitative real-time polymerase chain reaction (qRT-
PCR). For clathrin-mediated endocytosis, mRNA level of clathrin heavy chain (CHC) 
was further correlated with the protein level, and the activity of clathrin-mediated 
endocytosis was analyzed by fluorescence activated cell sorting (FACS).  
 
Present study yields valuable information about the endocytic pathways in the blood-
brain barrier. Better understanding of the endocytosis, their activity and functionality, in 
BBB aids developing efficient drug delivery systems to the brain. Knowledge of the 
active endocytic pathways present in BBB, enables development of nanoparticles that 
are targeted to use these active endocytic pathways. Targeted nanoparticles can serve a 
considerable tool to overcome the blood-brain barrier. 
 
 
5 MATERIALS AND METHODS 
 
5.1 Cell culture 
 
Cell culturing was performed in aseptic conditions. Laboratory ware and all the reagents 
were sterile. Cells were incubated in HeraCell 150, Thermo electron incubator at 37 ºC 
in 5 % CO2.  
 
5.2 Cell maintenance 
 
Cells were cultured on 75 cm² flasks at a density of 25 000 cells per cm², in a growth 
medium containing 5 % fetal bovine serum (FBS), 1 % penisillin-streptomycin, 0.05 % 
hydrocortisone, 0.5 % acid ascorbic, 1% chemically defined lipid concentrate, 1 % 
HEPES and 0.5 % human basic fibroblastic growth factor (bFGF) in endothelial basal 
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medium (EBM-2)). Flasks were 1 hour beforehand coated with the 150 µg/ml rat 
collagen I (3443-100-01, Cultrex). Growth medium was changed every second or third 
day. After 3-4 days cells reached confluence and they were either passed or used for 
experiments (until passage 35). Confluent cells were trypsinized with 0.25 % 
Trypsin/EDTA (25200, Gibco). Cell counter (Cedex XS, Innovatis) was used to 
determine the number of cells after trypsinization.  
 
5.3 Cell polarization studies 
 
For differentiation, cells were seeded on collagen coated 6 well PET cell culture inserts 
(3450, Costar) at 50 000 cells per cm². Medium was changed every second day. 
 
5.3.1 Lucifer yellow permeability  
 
To evaluate the tightness of the endothelial layer, the transmonolayer permeability of 
lucifer yellow (LY) was determined. In the transwell inserts, culture medium was 
replaced by 2.5 µg/ml  Lucifer yellow solution (0259, Sigma) in the transport buffer    
(1 % of HEPES 1M (15630-080, Gibco), 1 % of sodium pyruvate 100 mM (11360, 
Gibco) in 1XHBSS (14025, Gibco)). The inserts were transferred at 10, 25 and 45 
minutes to a new well containing transport buffer. Lucifer yellow fluorescence in 
sample corresponding to each timepoint was determined with a plate reader (Varioskan 
Flash 2.4.3, Thermo Scientific; excitation wavelength 425 nm, emission wavelength 
535 nm). Calibration curve was made and concentration of the marker molecules was 
calculated.  
 
5.3.2 Transepithelial electrical resistance 
 
Transepithelial electrical resistance (TEER) was measured to evaluate the tightness of 
the cell monolayer. TEER of cells grown for 1, 3, 7 and 10 days on transwell permeable 
support was measured in Endohm cup (ENDOHM-24SNAP, World precision 
instruments) with epithelial voltohmmeter (EVOM, World precision instruments). 
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5.3.3 Immunocytochemistry 
 
Formation of tight junctions, cell proliferation and localization of CHC protein was 
evaluated using immunocytochemistry (ICC). hCMEC/D3 cells were cultured on 
transwells for 1, 3, 7 and 10 days as described in section 5.3. Cells were washed with 
1X phosphate buffered saline (PBS) two times, fixed with 1 ml of 4 % 
paraformaldehyde (from Biocenter) per well for 10 minutes and washed three times 
with 1XPBS for 1 minute. Membranes were cut from transwells and stored in 1XPBS 
prior to further analysis. To permeabilize the cells, 1 ml of 0.1 % Triton-X100 (T8787, 
Sigma)  in 1XPBS was added on the membrane and incubated for 3 minutes. Cells were 
washed three times with 1XPBS for 1 minute. To reduce unspecific binding cells were 
incubated with 1 ml of blocking solution containing 2 % goat serum (S26, Sigma) and  
1 % bovine serum albumin (A2153, Sigma) in 1XPBS for 1 hour. Primary antibodies, 
ZO-1 (1:100, 10 µg/ml, 40-2200, Invitrogen), CHC (1:400, 2.5 µg/ml, Ab21679, 
Abcam), Ki67 (1:200, 5 µg/ml, Ab15580, Abcam) and negative control IgG (1:200,      
5 µg/ml, sc-2027, Santa Cruz biotechnology) were diluted in blocking solution and 
incubated with the cells for two hours in moist chamber at room temperature (200 
µl/membrane). Cells were washed three times with 1XPBS for 5 minutes. Then cells 
were incubated with secondary antibody (1:200, 5 µg/ml, Alexa Fluor 594, A11012, 
Invitrogen), for 1 hour in moist chamber at room temperature protected from light. Cells 
were washed three times with 1XPBS for 5 minutes, briefly rinsed in water and 
incubated with 200 µl of DAPI solution (1:400, 2.5µg/ml, D3417, Sigma) to stain the 
nucleus. Membranes were briefly rinsed in water, transferred to microscopic slides and 
mounted in VECTASHIELD hard set mounting medium (H-1400, Vector laboratories). 
Slides were stored at 4 ºC. Imaging was performed with Leica TCS SP5II HCS A 
confocal microscope with air objectives (HC PL APO 10x/0.4 and HC PL APO 20x/0.7 
CS) and immersion objective (HCX PL APO 20x/0.7 Imm Corr).  
 
5.3.4 Alkaline phosphatase expression 
 
The expression of alkaline phosphatase, the marker enzyme for a differentiated blood 
brain-barrier phenotype, was determined to evaluate the polarization level. hCMEC/D3 
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cells were cultured on transwells 1, 3, 7 and 10 days as described in Section 5.3. Sample 
collection was performed by lysing the cells with 1XRLB buffer (E397A, Promega).     
5 µl of sample of each day were transferred in duplicate to 96 well plate and 95 µ of 
dilution buffer (Great EscAPe SEAP Chemiluminescence Kit 2.0, 631736-8) were 
added to each sample well. Samples were incubated with 100 µl of SEAP substrate 
solution (Great EscAPe SEAP Chemiluminescence Kit 2.0, 631736-8) for 30 minutes in 
dark. Luminescence was measured with a plate reader (Varioskan Flash, 2.4.3, Thermo 
Scientific). 
 
5.4 RNA isolation 
 
hCMEC/D3 cells were cultured for 1, 3, 7 and 10 days of differentiation on transwells 
as described in Section 5.3 and then disrupted with 350 µl of RLT buffer (1015750, 
Qiagen), homogenized and kept at -20 C prior to further analysis. The total RNA was 
extracted by using Qiagen RNAeasy mini kit (74104) according to manufacturer’s 
instructions.  Briefly 350 µl of ethanol was added to the lysate. The sample was applied 
to the RNeasy mini spin in which total RNA binds to the membrane. Contaminants are 
efficiently washed away with RW1 buffer (1014567, Qiagen) and RPE buffer 
(1018013,Qiagen). High-quality RNA was eluted in 30 µl of RNase-free water 
(1017979, Qiagen). Bind, wash and elution steps were performed by centrifugation in a 
microcentrifuge. The concentration of RNA was determined by Nanodrop (Nanodrop 
ND-1000 spectrophotometer, Thermo scientific).  
 
5.5 RNA convertion to cDNA 
 
RNA samples were converted to cDNA by using the High Capacity RNA-to-cDNA Kit 
(4387406, Applied biosystems) according to manufacturer´s instructions. For each 
sample, 900 µg of RNA was converted to cDNA.  
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5.6 Protein extraction 
 
Protein samples were extracted for Western blot assay. hCMEC/D3 cells were cultured 
on transwells for 1, 3, 7 and 10 days before extraction as described in section 5.3. Cells                                    
were washed twice with ice-cold 1XPBS. To lyse the cells, 100 µl of cold RIPA buffer 
(89900, Thermo Scientific) containing protease inhibitor cocktail (78410, Thermo 
Scientific) was added to each well for 5 minutes. Lysate was transferred to a 
microcentrifuge tube and centrifuged at 15 000 g in cold for 15 minutes to pellet the cell 
debris. Supernatant was transferred to a new tube and stored at – 20 ºC prior to further 
analysis. 
 
5.7 Quantitative real-time polymerase chain reaction 
 
Quatitative real-time polymerase chain reaction (qRT-PCR) was used to evaluate the 
expression of specific endocytosis related proteins on mRNA level. hCMEC/D3 cells 
were cultured on transwells for 1,3,7 and 10 days as described in Section 5.3. Before the 
experiment, RNA was isolated and converted to cDNA as described in sections 5.4 and 
5.5. 18 µl of mixture (120 µl of  nuclease free water (NFW, 1012888, Qiagen), 60 µl of 
forward primer, 60 µl of reverse primer and 300 µl of FAST SYBR green master mix 
(4385612, Applied Biosystems)) was added to the wells of Micro Amp® Fast optical 96 
well reaction plate (Applied biosystems). Then 2 µl (10 ng) of each sample were added 
to the same wells with the mixture. 2 µl of NFW were added to the control wells. Plate 
was covered with an optical adhesive cover (4360954, Applied Biosystems) and run by 
qRT-PCR system (StepOne system, Applied biosystems). Primers which were used are 
described in Table 1. CHC, Caviolin 1 and RPLP0 were ordered from Sigma and other 
primers were from Oligomer. Results were normalized with RPLP0. Relative mRNA 
expression was calculated and the values were normalized to housekeeping gene 
RPLP0. Functions of each protein studied are presented in Table 2. 
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Table 1, Primer sequences. Abbreviations: F = forward primer, R = reverse primer 
Primer Sequence 
CHC F:TCTCTACTGATGAGCTTGTTGCTG 
R:GCTCCTCACAGCCCTCATG 
Caveolin 1 F:CGACGCGCACACCAAG 
R:TCTGGTTCTGCAATCACATCTTC 
Cavin 1 (Polymerase I and transcript 
release factor) 
F:AGATCAAGAAGCTGGAGGTCAA 
R:CTCCGACTCTTTCAGCGATTT 
Flotillin 1 F:CGAGGCAGAGAAGTCCCAACTA 
R:TGGCAAAGGCCTCAGCTT 
Flotillin 2 F:GGTGGTGTATCTCCGACACTC 
R:GATCTTCACCTGGGCGACAC 
AP2A1 (Adaptor-related protein complex 
2, alpha 2 subunit) 
F:TGTAAGAGCAAAGAGGCGGAAA 
R:GGCCAAGCAGGAAGATGAAAA 
AP2A2 (Adaptor-related protein complex 
2, alpha 2 subunit) 
F:GCAGCAGGTGGTCAACATAGAG 
R:GCCCCCATACCTGAACTGAA 
AP2B1 (Adaptor-related protein complex 
2, beta 1 subunit) 
F:TCGCCCTGAGGAACATCAA 
R:TCTGCCAGAACCTGAGCAATG 
AP2M1 (Adaptor-related protein complex 
2, mu 1 subunit) 
F:CCTCACTGCTGGCTCAGAAGA 
R:TGCACCCCGCTTGTGTT 
Cdc42 (cell division cycle 42) F:AGTGTGTTGTTGTGGGCGAT 
R:CTCAGCGGTCGTAATCTGTCA 
GRAF1 F:CAGGAGTCTCGGGTCTCTGA 
R:GAGTGGGTCCAAACACCACA 
RhoA F:TCGTTAGTCCACGGTCTGGT 
R:GTCTTTCCACAGGCTCCATCA 
Arf 1 (ADP-ribosylation factor 1) F:CCATTCCCACCATAGGCTTCA 
R:CATTGCTGTCCACCACGAAGAT 
PAK 1 (P21 protein (Cdc42/Rac)-
activated kinase 1 
F:TGAGGGAAAACAAGAACCCAAA 
R:TTCCATAACAACCCACAGCTCAT 
RPLP0 
 
F:AATCTCCAGGGGCACCATT 
R:CGCTGGCTCCCACTTTGT 
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Table 2. Characteristic proteins of specific endocytosis pathways studied in this project. 
CME = clathrin-mediated endocytosis; CavME = caveolin-mediated endocytosis; 
FlotME = flotillin-mediated endocytosis. 
 
Protein Pathway  Functions 
CHC CME Forming lattices during clathrin-mediated 
membrane traffic, involved in mitosis 
AP2 CME Links clathrin to plasma membrane 
Caveolin 1 CavME Role in cell polarization and migration functions, 
scaffolding of signaling proteins, cholesterol 
binding and homeostasis, regulation of endocytic 
trafficking 
Cavin 1 CavME Necessary for caveolae formation; regulates cell 
polarization and migration 
PAK 1 Macropinocytosis Involved in numerous cellular processes, several of 
which are through its interactions with the cell 
cytoskeleton modulators; involved in RhoA 
endocytosis 
Flotillin 1 FlotME Involved into cell-matrix adhesion, phagocytosis, 
exocytosis, and several signaling pathways 
Flotillin 2 FlotME The same as for flotillin 1 
Cdc42 CLIC-GEEC RhoGTPase. mediates cell polarity and filipodia, 
also regulates phagocytosis  
Arf1 CLIC-GEEC GTPase. A central role in vesicle formation 
GRAF1 CLIC-GEEC Not clear. Coating protein? 
RhoA RhoA-dependent 
E. 
RhoGTPase 
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5.8 Western Blotting 
 
Protein concentration of the hCMEC/D3 samples was determined by the kit (Pierce™ 
BCA Protein Assay Kit, 23227, Thermo Scientific). The samples were diluted two times 
with a sample buffer, heated for 5 min at 95 ºC for protein denaturation and frozen prior 
to further studies. Protein samples from hCMEC/D3 cells and molecular weight markers 
(high molecular weight marker (161-0309, Biorad) and low molecular weight marker 
(161-0305, Biorad) were separated by gel electrophoresis and then transferred to 
nitrocellulose membrane (162-0145, BioRad). Non-specific binding sites were blocked 
by 5 % milk in 1 X Tris-buffered saline (TBS; 25 mM Tris, 150 mM NaCl, 2 mM KCl, 
pH 7.4) containing 0.1 % Tween 20 (P5927, Sigma) for 1 hour at room temperature.  
Membrane was incubated with primary antibody, CHC (1:2000, 0.5 µg/ml, 610499, 
BD) in 5 % milk in 1 X Tris-buffered saline with Tween (TBST; 25 mM Tris, 150 mM 
NaCl, 2 mM KCl, Tween pH 7.4), for 1 hour at room temperature. Horseradish 
peroxidace (HRP) -conjugated Goat-anti-mouse ZyMax (1:2000, 0.5 µg/ml, 816520, 
Zymed) was applied as secondary antibody for 45 minutes at room temperature. 
Between incubations, membranes were washed with 1XTBST first 15 minutes and then 
3 times 5 minutes. To reveal immunoreactive bands, the blots were incubated in ECL 
Plus reagent for 1 min (RPN 2106, GE Healtcare Lifesciences) and detected by camera 
after 1 min and 5 min expose (M35 X-OMAT Processor, Kodak). 
 
5.9 Fluorescence-activated cell sorting 
 
Uptake of transferrin (specific marker of clathrin-mediated endocytosis) was determined 
by fluorescence-activated cell sorting (FACS). hCMEC/D3 cells were seeded to 
transwells 10, 7 and 1 day prior to uptake experiment. Uptake experiment was made to 
both directions (from apical to basolateral and basolateral to apical direction). Cells 
were washed with warm HEPES medium (25 mM of 1M HEPES (15630-056, 
Invitrogen) in EBM-2 medium (190860, Lonza)). 500 µl of HEPES medium containing 
5 µg/ml of transferrin (F0895, Sigma) was added to apical compartments for apical to 
basolateral uptake study and 2000 µl to the basolateral compartments for basolateral to 
apical uptake study. Opposite compartment was filled with HEPES medium. After 5 
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minutes incubation at 37 ºC, cells were washed two times with ice-cold HEPES buffer 
(1M, 15630-056, Invitrogen) to remove excess of transferrin and to stop endocytosis. To 
remove the surface-bound transferrin and detach the cells, 600 µl of ice-cold pronase (2 
mg/ml (P5147, Sigma) in HEPES medium) was added to the wells for 1 hour. Detached 
cells were transferred to eppendorf tubes. Samples were centrifuged twice and pellet 
resuspended in ice-cold HEPES buffer. Cells were analyzed by using a FACS BD LSR 
II Flow Cytometer (BD, San Jose, CA, USA) operating under the DIVA software 
(Version 6.0). For each sample, 10 000 events were collected after gating of the living 
cell population by forward/side scatter, and the mean fluorescence of the living cells 
was determined at 488 nm. 
 
 
6 RESULTS 
 
6.1 Lucifer yellow permeability 
 
To evaluate the integrity of the endothelial layer, the transmonolayer permeability of 
lucifer yellow was determined. LY is a highly hydrophilic, low molecular weight tracer 
molecule that indicates paracellular transport across the tight junctions, which also 
indicates the polarization level of hCMEC/D3 cells. Low lucifer yellow permeability 
indicates tightness of the cell layer, but also high polarization. As shown in figure 5, the 
apparent permeability coefficient of lucifer yellow on hCMEC/D3 cells decreased from 
day 1 to day 7, approximately 3 fold, from 0.00194 cm/min to 0.00061 cm/min (Figure 
5). On day 10, Papp started to increase and reached the permeability 0.00127 cm/min, 
which was approximately same level as on day 3. 
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Figure 5, The apparent permeability coefficients of Lucifer Yellow on hCMEC/D3 
cells after 1, 3, 7 and 10 days of differentiation on transwells (mean from 3 
independent experiments ± SD).  
 
 
 
6.2 Transendothelial electrical resistance 
 
Transendothelial electrical resistance of hCMEC/D3 cells is indicative of the tightness 
of the endothelial layer, which is also related to the cell polarization level. TEER was 
expected to increase when cultured longer due to tight junction formation between 
contacting confluent cells. On day 1 the TEER value was 0 Ω·cm² as seen in the Figure 
6. On day 3 TEER was 9.3 Ω·cm² and on day 7 TEER was 15.5 Ω·cm². The highest 
TEER was measured on day 10 and it was 35.65 Ω·cm² (Figure 6).  
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Figure 6, Transepithelial electrical resistance (TEER) of hCMEC/D3 cells after 1,  
3, 7 and 10 days of differentiation on transwells (mean ± SD n = 2). TEER was 
measured in Ehdohm cup with epithelial voltohmmeter.  
 
 
6.3 Immunofluorescence 
 
Tight junction formation, proliferation level and clathrin-heavy chain (CHC) protein 
expression was characterized using immunofluorescence. Tight junction formation was 
analyzed by staining specific endothelial tight junction marker protein ZO-1. High 
expression of ZO-1 indicates higher tight junction formation as well as higher integrity 
of the barrier which is also indicative of higher cell polarization. As seen in Figure 7, 
expression of ZO-1 increased together with increased cell density from day 1 to day 10.  
 
Proliferation level was analyzed to verify if the hCMEC/D3 cells exhibit contact 
inhibition, in other words, if they stop dividing when they reach confluence by staining 
Ki67, a nuclear protein expressed only in proliferating cells. All the hCMEC/D3 cells 
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were actively proliferating from day 1 to day 10 even though the cells have obviously 
reached the confluence already on day 7. However, on day 10 there are much less 
proliferating cells than on day 7 (Figure 8).  
 
Clathrin heavy-chain (CHC) was stained to visualize the expression of this protein as a 
function of cell polarization. CHC is directly involved into clathrin-mediated 
endocytosis, therefore the expression of this protein could be indicating the presence of 
this pathway. As seen in Figure 9, CHC is strongly expressed in cells at all studied time 
points. There seem to be no remarkable differences in the level of CHC expression from 
day 1 until day 10. 
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Figure 7, Confocal microscopy images of tight junctions in hCMEC/D3 cells after 
1, 3, 7 and 10 days of differentiation on transwells.  ZO-1 (red) was used as a marker 
of tight junctions. Nuclei (blue) were stained with DAPI.  
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Figure 8, Confocal microscopy images of hCMEC/D3 cells after 1, 3, 7 and 10 days 
of differentiation on transwells. Proliferating cells (red) were stained by proliferation 
nuclear marker Ki67 and nuclei (blue) with DAPI. 
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Figure 9, Confocal microscopy images of clathrin localization in hCMEC/D3 cells 
after 1, 3, 7 and 10 days of differentiation on transwells. Protein CHC (red) was 
stained with CHC specific antibody and nuclei (blue) with DAPI. 
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6.4 Alkaline phosphatase expression  
 
To evaluate the differentiation of the hCMEC/D3 cells, expression of alkaline 
phosphatase (ALP), the marker enzyme of differentiated BBB phenotype, was 
determined. Cell On day 1 expression of total ALP was 6.6 µg/mg, on day 3 it was  10.6 
µg/mg , on day 7 it was 10.8 µg/mg and on day it started to decrease and it was 6.7 
µg/mg (Figure 10). Concentration of total protein of alkaline phosphatase was increased 
from day 1 to day 7 but was decreased on day 10, which is showing same kind of trend 
with other polarization studies, except TEER. 
 
 
 
Figure 10, Expression of alkaline phosphatase in hCMEC/D3 cells after 1, 3, 7 and 
10 days of differentiation on transwells (mean from 2 independent experiments ± 
SD).  
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6.5 Quantitative real-time polymerase chain reaction  
 
Expression of proteins which are characteristic for each endocytic pathway was 
determined at mRNA level by quantitative real-time polymerase chain reaction (qRT-
PCR). We were interested to see how polarization affects different endocytic pathways 
on mRNA level. To follow cell polarization in time, we were growing the cells on 
transwell supports for 1, 3, 7 or 10 days followed by qRT-PCR analysis.. 
 
Five proteins are related to clathrin-mediated endocytosis, clathrin heavy chain (CHC) 
and four adaptor protein-2 (AP2) proteins (AP2A1, AP2A2, AP2B1, AP2M1). The 
level of AP2 proteins remained at the same level at all tested time points. In contrast, 
mRNA expression of CHC increased about 30 % from day 1 to day 7 and on day 10 
decreased (Figure 11). The amount of flotillin-mediated endocytosis related proteins did 
increase in about 50 % (flotillin 1) and 170 % (flotillin 2) on mRNA level from day 1 to 
day 7, but then slightly decreased on day 10. mRNA expression of macropinocytosis 
related protein PAK 1 increased from day 1 to day 10 about 100 % . mRNA expression 
of RhoA-dependent endocytosis related protein remained the same as well as clathrin-
independent carrier (CLIC) / GPI-AP-enriched early endosomal compartment (GEEC) 
endocytosis (CLIC/GEEG) related proteins. The mRNA level of caveolin-mediated 
endocytosis related protein cavin 1 remained the same, whereas caveolin 1 expression 
decreased about 50 % between day 3 and 7. In general, mRNA expression of most of 
the studied proteins did not considerably change during 10 days of cell polarization on 
transwell permeable support. 
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Figure 11, Relative mRNA expression of characteristic genes of endocytic 
pathways in hCMEC/D3 cells quantified by quantitative real-time polymerase 
chain reaction (qRT-PCR). A) Clathrin heavy chain (CHC) and B) four adaptor 
protein-2 (AP-2) proteins (AP2A1, AP2A2, AP2B1, AP2M1) are characteristic for 
clathrin-mediated endocytosis. C) Flotillin 1 and flotillin 2 are characteristic for 
flotillin-dependent endocytosis. D) Macropinocytosis is dependent of protein PAK 1. E) 
Protein RhoA is characteristic for RhoA-dependent endocytosis. F) Clathrin-
independent carrier (CLIC) / GPI-AP-enriched early endosomal compartment (GEEC) 
endocytosis (CLIC/GEEC) is dependent of the small GTPases, Cdc42 and GRAF1, and 
ADP-ribosylation factor, arf1. G) Proteins caveolin 1 and cavin 1 are characteristic for 
caveolin-mediated endocytosis. 
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6.6 Western Blot 
 
mRNA level of the protein does not necessarily correlate with the actual protein level. 
Based on the data from qRT-PCR, CHC expression decreased approximately 33 % after 
10 days of differentiation in comparison to day 1. To investigate if the same trend can 
be seen at the protein level, we performed western blot to visualize CHC protein 
expression. CHC is related to clathrin-mediated endocytosis. Expression of CHC 
protein in hCMEC/D3 cells after 1, 7 and 10 days was not remarkably changed (Figure 
12). 
 
 
Figure 12, Expression of CHC protein in hCMEC/D3 cells visualized by western 
blot. Amount of the protein sample was 3,7 µg/well. Molecular weight of CHC is 180 
kD. The cells were grown on transwell permeable supports for 1, 7 and 10 days in A, B, 
C, respectively.  
 
45 
 
6.7 Fluorescence-activated cell sorting 
 
To study the activity of clathrin-mediated endocytosis as a function of cell polarization, 
uptake of fluorescently-labeled transferrin was determined using fluorescence - 
activated cell sorting (FACS). Transferrin is a specific marker of CME. Because the 
membrane supporting cells might either bind some transferrin or prevent the free access 
of transferrin to the basolateral side of the cells, the uptake results from one direction 
cannot be directly compared with the results from another direction.  
 
According to our data, transferrin uptake in both directions was slightly (20-25 %) 
increased from day 1 to day 7 (Figure 13). On day 10 uptake in both apical to 
basolateral and basolateral to apical direction went back to the day 1 level. These results 
indicate light increase in the activity of clathrin - mediated endocytosis from apical to 
basolateral as well as from basolateral to apical direction. 
 
 
 
Figure 13, Transferrin uptake (specific marker of clathrin-mediated endocytosis) 
in hCMEC/D3 cells analysed by fluorescence-activated cell sorting after 1, 7 and 10 
days of cell differentiation on transwells. 
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7 DISCUSSION 
 
Nanoparticles have been shown to be promising tools to deliver drugs to the brain, but 
the exact endocytosis mechanism leading to efficient penetration via BBB is not fully 
understood. More studies are needed to set up the link between uptake mechanism and 
brain delivery efficiency in order to make the design of nanoparticles more effective 
(Smith and Gumbleton, 2006 ; Sandvik et al, 2011; Wolfart et al, 2012). In such studies 
careful characterization of the BBB cell model is highly important to get as reliable data 
as possible. Blood-brain barrier endothelial cells are known to be well polarized in vivo 
(Abbott et al, 2008). In the present study we aim to characterize polarization status of 
hCMEC/D3 cells, which have been widely utilized as in vitro BBB cell model. 
Furthermore, we aimed to investigate how polarization influences endocytic processes 
in these cells. 
 
In our study maximum TEER observed for hCMEC/D3 cells in our study was almost 
100 times lower than TEER of brain endothelial cells in vivo, that is approximately 
1000 Ω·cm² (Butt et al, 1990). Low TEER indicates that hCMEC/D3 cells are far 
leakier than the brain endothelial cells in vivo. This leakiness is common in all 
immortalized cell lines due to absence of proper paracellular barrier properties 
(Gumbleton and Audus, 2001). Due to the leakiness of the hCMEC/D3 cells they are 
not an optimal model for permeability transport studies. However, nanoparticles are 
relatively large in size and cannot permeate through the paracellular route, therefore the 
leakiness is not a considerable problem in nanoparticle uptake studies (Hillaireau and 
Couvreur, 2009). 
 
hCMEC/D3 cells have been widely used  in nanoparticle uptake experiments (dos 
Santos et al, 2011, Georgieva et al, 2011; Georgieva et al, 2012). Most of the uptake 
experiments have been done with polarized cells but some have been made with non-
polarized cells (Chattopadhyay et al, 2008; Markoutsa et al, 2011; Ragnaill et al, 2011; 
Pinzon-Daza et al, 2012). To polarize the hCMEC/D3 cells, they were cultured on 
transwells. However, polarization status has not always been confirmed, even though it 
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is very important, because it has been shown that nanoparticle internalization decreases 
when the hCMEC/D3 cells are polarized (Ragnaill et al, 2011).  
 
In those studies where polarization level has been confirmed, it has been done by 
transendothelial electrical resistance measurements and sometimes also by paracellular 
permeability tests (Ragnaill et al, 2011: Pinzon-Daza et al, 2012). In our hands highest 
TEER was observed at day 10. However, the results from other polarization status 
studies such as lucifer yellow permeability (Figure 5), ZO-1 staining (Figure 7), alkaline 
phosphatase expression (Figure 10) and proliferation marker expression (Figure 8) show 
the same trend that polarization was increased until day 7 and then decreased on day 10. 
In vivo brain endothelial cells form a uniform well-polarized monolayer which exhibits 
contact inhibition (Abbott et al, 2008). Our results show that hCMEC/D3 cells continue 
proliferating even though they have reached the confluence (Figure 8). Therefore, the 
cells start growing as a multilayer, which have negative influence on their polarization. 
This might be the reason why lucifer yellow permeability and alkaline phosphatase 
activity assays indicate lower polarization of cells on day 10 in comparison to day 7, 
whereas TEER increases. These results indicate that TEER measurements have to be 
supported by other methods to demonstrate the cell polarization.  
 
Our polarization studies are in line with the previous studies made by other laboratories. 
Lucifer yellow permeability was the same order of magnitude as in other studies in the 
literature (Poller et al, 2008). TEER in hCMEC/D3 cell line was as low in our work as 
in the other works (Weksler et al, 2005; Ragnaill et al, 2011). Positive staining for tight 
junctional protein ZO-1 has been demonstrated by the others as well as in our study 
(Weksler et al, 2005). The most used seeding density has been 50 000 cells per cm² 
(Poller et al, 2008; Ragnaill et al, 2011). Weksler and colleagues (2005) used seeding 
density 20 000 cells per cm². Usually hCMEC/D3 cells have been used on days 7 to10 
(Ragnaill et al, 2011). In our hands hCMEC/D3 cells seeded at the density 50 000 cells 
per cm² are best polarized on day 7; therefore this is the optimal time point to perform 
studies with hCMEC/D3 cells. Overall, even though the polarization level increased to 
some extent, our results indicate that hCMEC/D3 cells were not well polarized due to 
small differences on polarization levels between early and late time points.  
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dos Santos et al (2011) performed the comparative study investigating the effect of 
particle size on the in vitro cell uptake in several cell lines, including hCMEC/D3 cells, 
HeLa cells, A549 epithelial cells, 1321N1 astrocytes and murine RAW 264.7 
macrophages. hCMEC/D3 cells showed unexpectedly high uptake of nanoparticles in 
comparison to other cell lines. This was unexpected as brain endothelial cells in vivo are 
known to have reduced endocytic activity (Ragnaill et al, 2011). The experiments were 
performed in cells grown on plastic for 24 hours and incubated with nanoparticles. The 
use of non-polarized cells might have resulted in very different endocytic activity from 
highly polarized cells in BBB in vivo. 
 
Nanoparticle uptake usually decreases when cells are polarized. For instance, Matsui et 
al (1997) demonstrated that internalization of liposome-DNA complexes in airway 
epithelial cells decreased when cells were differentiated. Internalization of nonviral 
gene delivery vectors, such as Lipofectin and polylysine, in CaCo-2 cells was decreased 
approximately 1000 fold in differentiated cells in comparison to non-differentiated cells 
(Cryan and O´Driscoll, 2003). Brain endothelial cells are known to be well polarized in 
vivo and also demonstrate very low endocytic activity (Smith and Gumbleton, 2006; 
Ragnaill et al, 2011). However, our data obtained in hCMEC/D3 cells demonstrated the 
lack of considerable changes in mRNA expression of proteins characteristic of different 
endocytic pathways with cell polarization in most cases. One possible explanation can 
be the fact that our polarization characterization studies demonstrated overall low level 
of polarization of hCMEC/D3 cells even after 7 days on transwell permeable support.  
 
Furthermore, it is important to remember that mRNA levels do not necessary correlate 
with protein levels (Vogel and Marcotte, 2012). Therefore it is possible, that although 
no changes were observed at the mRNA level, the amount of corresponding protein 
and/or the activity of the corresponding endocytic pathways were still changed as 
function of cell polarization. Whereas, reduction of mRNA observed for such proteins 
as CHC and caveolin-1 might not lead to the decreased expression of corresponding 
proteins. To check this hypothesis, we chose CHC protein as an example to see the 
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expression of CHC on protein level and for transferrin uptake study to see the activity of 
the clathrin-mediated pathway.  
 
Our results showed, that there was not remarkable difference in CHC expression on 
protein level on different time points, but mRNA expression of CHC was decreased 
approximately 30 % from day 1 to day 10. Inconsistency between CHC mRNA and 
protein expression might be due to gene regulation of the cell (Vogel and Marcotte, 
2012). Cells are able to regulate the protein synthesis by influencing in the mRNA and 
probably not all mRNA is translated to protein. Gene expression is controlled many 
different ways, mostly by post-transcriptional, translational and protein degradation 
regulation. These factors explain mostly why the changes in mRNA level do not 
correlate with protein levels. Additionally, differences in sensitivity between methods of 
protein and mRNA quantification must be taken into account. Conventional Western 
blot is not quantitative whereas qRT-PCR is quantitative and highly sensitive method. 
Therefore, it is possible, that less than 2 times decrease in mRNA level between day 1 
and day 10 is not big enough to be detected by western blot.  
 
For clathrin-mediated endocytosis good correlation was observed between mRNA 
expression and the activity of the pathway. It would have been highly valuable to see if 
the same correlation can be observed for other endocytosis-related proteins. 
Unfortunately, there are no specific markers for most of the endocytic pathways, 
making it impossible to measure the activity of these pathways (Doherty and McMahon, 
2009). However we can speculate that such a correlation is unlikely to be found for 
proteins which have multiple functions in the cell. For example Cdc42 and GRAF1 are 
kinases with multiple functions in regulation of cell morphology, cell cycle and 
migration (Hall, 1998; Erickson and Cerione, 2001; Doherty et al, 2011). 
 
 
8 CONCLUSIONS 
 
In the present study we characterized polarization status of hCMEC/D3 human brain 
endothelial cell line, which is widely used as BBB in vitro model. It was shown that 
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hCMEC/D3 cells are best polarized after growing on transwell permeable support for 7 
days. At the later time points, the cell polarization started to decrease, probably due to 
multilayer formation. As the TEER of the cells growing in the multilayer is increase in 
comparison to monolayer cells, we conclude that measuring TEER alone is not a 
reliable method to determine polarization status of the cells. 
 
RNA expression of most of endocytosis-related proteins did not change remarkably 
during 7 days of cell polarization on transwell permeable supports which is in a good 
agreement with overall poor polarization of hCMEC/D3 cell model. In case of clathrin-
mediated endocytosis no correlation between CHC mRNA and protein level was 
observed. However, good correlation between CHC mRNA level and activity of the 
pathway was found. It would be interesting to study if the same trend can be observed 
for other endocytic pathways. 
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